

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Laekna, Inc.**

**來凱醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2105)**

## **VOLUNTARY ANNOUNCEMENT**

### **SUBMISSION OF IND AMENDMENT TO U.S. FDA FOR LAE102 FOR THE TREATMENT OF OBESITY**

This announcement is made by Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that the Group has submitted an Investigational New Drug (“**IND**”) amendment to the U.S. Food and Drug Administration (the “**U.S. FDA**”) for LAE102 for the treatment of obesity.

In April 2024, the Group has obtained the IND approval from the U.S. FDA for LAE102 for the treatment of obesity. In November 2024, the Group entered into a clinical collaboration agreement with Eli Lilly and Company (“**Lilly**”) (NYSE: LLY) to support and accelerate global clinical development of LAE102 for the treatment of obesity. Lilly will be responsible for the execution and funding of a phase I study in the U.S. (the “**U.S. Phase 1 Clinical Trial**”). The Group retains global rights for LAE102. The U.S. Phase 1 Clinical Trial is expected to commence in the second quarter of 2025.

The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.

#### **ABOUT LAE102**

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising drug candidate for achieving quality weight control.

**RISK WARNING**

**LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.**

By Order of the Board  
**Laekna, Inc.**  
**Dr. LU Chris Xiangyang**  
*Chairman*

Hong Kong, March 31, 2025

*As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.*